News: Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Consolidated Issue listed on NASDAQ Global Market

36.91USD
17 May 2013
Price Change (% chg)

$1.40 (+3.94%)
Prev Close
$35.51
Open
$35.51
Day's High
$37.11
Day's Low
$35.14
Volume
1,378,336
Avg. Vol
1,981,439
52-wk High
$45.00
52-wk Low
$2.60

Search Stocks
Select another date:

Tue, Apr 16 2013

Sarepta shares fall on FDA guidance on drug, but analysts divided

- Sarepta Therapeutics Inc's shares were set to open 11 percent lower on Tuesday after U.S. health regulators asked for more data to consider its rare disease drug for a faster approval track, but analysts were divided on whether this was a setback.

Continue Reading

FDA seeks more data on Sarepta muscular dystrophy drug

- Sarepta Therapeutics Inc said U.S. health regulators have asked for additional information on its experimental drug to treat a rare degenerative disease in boys.

BRIEF-Sarepta Therapeutics shares down 9.5 pct after the bell

NEW YORK, April 15 - Sarepta Therapeutics Inc : * Shares down 9.5 percent after the bell

FDA asks for additional info on Sarepta's muscular dystrophy drug

April 15 - Sarepta Therapeutics Inc said U.S. health regulators have asked for additional information on its experimental drug intended to treat young boys suffering from a rare degenerative disease.

New-look Sarepta eyes approval for muscular dystrophy drug

- After three decades without bringing a drug to market, Sarepta Therapeutics Inc stands on the verge of a breakthrough with its treatment for a crippling genetic disorder that affects one in every 3,500 newborn boys.

New-look Sarepta eyes approval for muscular dystrophy drug

* Under new CEO, Sarepta focused on Duchenne muscular dystrophy drug

Sarepta Therapeutics set to rise if seeks quick drug OK-Barron's

NEW YORK, March 24 - Shares of Sarepta Therapeutics could rise swiftly and hit $50 a share if it seeks accelerated approval from the U.S. Food and Drug Administration for eteplirsen, a drug being tested for Duchenne muscular dystrophy, according to a report in Barron's financial newspaper.

Second Twitter hoax in two days smacks another stock

NEW YORK - Sarepta Therapeutics Inc became the second company in as many days to see its shares plunge as a result of a Twitter hoax on Wednesday after a user posed as an influential short-seller and alleged improprieties at the biopharmaceutical company.

RPT-UPDATE 1-Second Twitter hoax in two days smacks another stock

NEW YORK, Jan 30 - Sarepta Therapeutics Inc became the second company in as many days to see its shares plunge as a result of a Twitter hoax on Wednesday after a user posed as an influential short-seller and alleged improprieties at the biopharmaceutical company.

Select another date:

Market Views

» More SRPT.O Market Views

Press Releases

Search Stocks